2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Nom du produit CAS No. Pureté Chemical Structure
  • HY-W331017
    1-Hexacosanoyl-sn-glycero-3-phosphocholine 1213783-80-2 98%
    1-Hexacosanoyl-sn-glycero-3-phosphocholine (26:0 Lyso PC) is a long-chain fatty acid. 1-Hexacosanoyl-sn-glycero-3-phosphocholine can be used as a biomarker for X-linked adrenoleukodystrophy (ALD) in mice.
    1-Hexacosanoyl-sn-glycero-3-phosphocholine
  • HY-W335927
    MAO-B-IN-19 152897-41-1 98%
    MAO-B-IN-19 is a selective MAO-B inhibitor with an IC50 of 0.67 μM. MAO-B-IN-19 shows neuroprotective and anti-inflammatory properties.
    MAO-B-IN-19
  • HY-W335976
    Almotriptan hydrochloride 154323-46-3 98%
    Almotriptan (PNU180638) hydrochloride is an orally active, highly selective agonist of the 5-HT1B/1D receptor (5-HT1B/1D receptor), with EC50 values of 1.6 nM and 3.1 nM, respectively. Almotriptan hydrochloride shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan hydrochloride induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan hydrochloride can be used in research related to migraine.
    Almotriptan hydrochloride
  • HY-W337358
    N-(3-Hydroxyphenyl)-arachidonoyl amide 183718-75-4 98%
    N-(3-Hydroxyphenyl)-arachidonoyl amide (Compound 23) is an anandamide transport inhibitor with an IC50 of 21.3 μM.
    N-(3-Hydroxyphenyl)-arachidonoyl amide
  • HY-W344115
    Bicifadine 71195-57-8 98%
    Bicifadine is an orally active serotonin/norepinephrine/dopamine triple reuptake inhibitor. Bicifadine is an effective antinociceptive in several models of acute, persistent, and chronic pain.
    Bicifadine
  • HY-W348226
    MMDPPA 858215-05-1 98%
    MMDPPA is an amphetamine and is a precursor in the synthesis of MDA.
    MMDPPA
  • HY-W354617
    Roxadimate 58882-17-0 98%
    Roxadimate (Ethyl dihydroxypropyl PABA) can be used as a sunscreen agent by scavenging free radicals and reducing oxidative stress. Roxadimate can protect cells from damage caused by radiation or neurotoxic insults. Roxadimate can be studied in research for cancer and neurodegenerative conditions.
    Roxadimate
  • HY-W370556
    (Rac)-LM11A-31 289475-77-0 98%
    (Rac)-LM11A-31 is a racemate of LM11A-31. LM11A-31 is a non-peptide modulator of p75NTR (neurotrophin receptor p75) and is an orally effective proNGF antagonist.
    (Rac)-LM11A-31
  • HY-W385577
    (S)-2-Benzylpyrrolidine 97522-31-1 98%
    (S)-2-Benzylpyrrolidine (Compound s1) serves as a METH hapten scaffold. (S)-2-Benzylpyrrolidine attenuates Methamphetamine-induced hyperlocomotion, hyperthermia and respiratory depression. (S)-2-Benzylpyrrolidine alleviates Fentanyl-induced respiratory depression.
    (S)-2-Benzylpyrrolidine
  • HY-W392413
    Glutathione monoethyl ester 118421-50-4 98%
    Glutathione monoethyl ester is a glutathione derivative that can be transported into cells and hydrolyzed into glutathione. Glutathione monoethyl ester downregulates the gene expression of TEN1 and CTC1 while upregulating TERT expression. Glutathione monoethyl ester enhances telomerase activity, promotes proliferation and differentiation in aged bone marrow stromal cells, while elevating glutathione levels and reducing oxidative stress, protein aggregation and cell death in motor neuronal cells. Glutathione monoethyl ester confers broad multi-organ protection against cerebral ischemia, renal injury, liver damage, and pancreatitis. Glutathione monoethyl ester can be used for the research of amyotrophic lateral sclerosis, stroke, acute renal failure, liver injury, and acute pancreatitis.
    Glutathione monoethyl ester
  • HY-W396714
    Succinic acid sodium 14047-56-4 98%
    Succinic acid sodium is a potent and orally active anxiolytic agent. Succinic acid sodium shows inhibitory effects on colonic epithelial cell proliferation in vivo. Succinic acid sodium can down-regulate the expression of KCNMB1 (potassium channel subunit β1) and TET1 (ten?eleven translocation 1). Succinic acid sodium can be used for gestational hypertension research.
    Succinic acid sodium
  • HY-W399025
    ID110460001 1110883-26-5 98%
    ID110460001 is a full agonist of μ-opioid receptor and an agonist of δ-opioid receptor. ID110460001 exhibits high intrinsic efficacy for G protein pathway activation of μ-opioid receptor, and this property is not affected by the reduction in receptor quantity. ID110460001 acts only as a very weak partial agonist in the β-arrestin-2 pathway of both receptors, and binds to μ-opioid receptor via a specific mode. The efficacy of ID110460001 in the G protein pathway of δ-opioid receptor is sensitive to changes in receptor quantity. ID110460001 can be used in pain-related research.
    ID110460001
  • HY-W399186
    Methylclonazepam 5527-71-9 98%
    Methylclonazepam is a benzodiazepine with anxiolytic activity. Methylclonazepam inhibits the absorption of 5-hydroxytryptamine by Schistosoma mansoni. Methylclonazepam derivatives have anti-Schistosoma mansoni activity.
    Methylclonazepam
  • HY-W402208
    MAP4K4-IN-7 1499162-60-5 98%
    MAP4K4-IN-7 (Compound 8) is a MAP4K4 inhibitor. MAP4K4-IN-7 shows moderate inhibitory activity against TNIK, MAP4K4, and MINK1 with pIC50 values of 6.8, 6.8, and 6.7 respectively. MAP4K4-IN-7 can be used for the researches of cancer and neurological disease, such as schizophrenia.
    MAP4K4-IN-7
  • HY-W403075
    N-(3-Methoxybenzyl)stearamide 1429659-99-3 98.04%
    N-(3-Methoxybenzyl)stearamide a natural product from Lepidium meyenii (Maca), inhibits human and mouse soluble epoxide hydrolase (hsEH and msEH) with IC50s of 0.001 and <0.001 μg/nM, respectively.
    N-(3-Methoxybenzyl)stearamide
  • HY-W408969
    4-Methoxy PCE hydrochloride 1933-15-9 98%
    4-Methoxy PCE hydrochloride is an arylcyclohexylamine.
    4-Methoxy PCE hydrochloride
  • HY-W414109
    ID110460002 1172882-21-1 98%
    ID110460002 possesses both full agonist activity at the μ-opioid receptor (OPRM) and agonist activity at the δ-opioid receptor (OPRD). ID110460002 acts as a potent agonist for the G protein pathways of both receptors, but exhibits only very weak partial agonist activity towards the β-arrestin-2 pathway. The agonistic potency of ID110460002 at OPRM has extremely high intrinsic activity and is unaffected by reduced receptor expression levels, while its potency at OPRD depends on receptor expression levels. ID110460002 displays tissue- or organ-dependent properties, and serves as a critical compound for investigating pain mechanisms and analgesia.
    ID110460002
  • HY-W414498
    1-Deoxysphingosine 193222-34-3 98%
    1-Deoxysphingosine is elevated in lymphoblasts of individuals with hereditary sensory neuropathy type 1 (HSAN1) disorder; it features a (4E) double bond in its structure and is produced through the catabolism of 1-deoxyceramide catalyzed by the ceramidase enzyme, classifying it as an unsaturated deoxy-sphingoid base.
    1-Deoxysphingosine
  • HY-W414824
    3β,7β-Dihydroxy-5-cholestenoic acid 1246298-66-7 98%
    3β,7β-Dihydroxy-5-cholestenoic acid is a C27 acid that displays elevated levels in Niemann-Pick type C and Niemann-Pick type B diseases, contributing to toxicity in oculomotor neurons. It is synthesized from 3β-hydroxy-7-oxocholest-5-en-(25R)26-oic acid (3βH,7O-CA) through the enzymatic action of hydroxysteroid 11-β dehydrogenase 1.
    3β,7β-Dihydroxy-5-cholestenoic acid
  • HY-W415121
    Bupivacaine hydrochloride monohydrate 73360-54-0 98%
    Bupivacaine hydrochloride monohydrate is a NMDA receptor inhibitor. Bupivacaine hydrochloride monohydrate can block sodium, L-calcium, and potassium channels. Bupivacaine hydrochloride monohydrate potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride monohydrate can be used for the research of chronic pain.
    Bupivacaine hydrochloride monohydrate
Cat. No. Nom du produit / Synonyms Application Reactivity